Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,262 across all filing types
Latest filing 2023-07-21 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
关于使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company about the progress of using idle funds for cash management, including details of financial products purchased, risk control measures, and impact on the company. It is a regulatory disclosure about financing activities but does not contain comprehensive financial statements or detailed financial performance data. The document length is about 6,000 characters, which is relatively short and focused on a specific financing update rather than a full report. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2023-07-21 Chinese
2023年半年度业绩预增公告
Earnings Release Classification · 95% confidence The document is titled as a "2023 年半年度业绩预增公告" which translates to "2023 Half-Year Performance Increase Forecast Announcement." It provides estimated financial results for the half-year period ending June 30, 2023, including expected net profit and revenue growth percentages. The document explicitly states that the forecast has not been audited by a registered accountant and that the actual financial data will be disclosed in the official 2023 half-year report. The document is short (1368 characters) and serves as a performance forecast announcement rather than a full interim or quarterly report containing actual financial statements or detailed analysis. Therefore, it is best classified as an Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights only. H1 2023
2023-07-13 Chinese
关于布洛芬混悬液获得上市许可受理的公告
Regulatory Filings Classification · 100% confidence The document is a short announcement (857 characters) from a company disclosing receipt of a drug registration acceptance notice from the National Medical Products Administration. It contains no financial data, no detailed financial statements, no management discussion, no voting results, no executive changes, no earnings information, and no regulatory certifications. It is an official announcement about a regulatory approval process for a pharmaceutical product. The document is not a report itself but an announcement of a regulatory event. Given the short length and nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-06-20 Chinese
2022年年度权益分派实施公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the implementation of the 2022 annual dividend distribution plan approved at the 2023 annual general meeting. It details the dividend amount per share, the record date, the ex-dividend date, and the method of dividend payment. It explicitly states the dividend distribution scheme and the relevant dates but does not contain financial statements or comprehensive financial performance data. The document length is 2361 characters, which is relatively short and focused solely on dividend distribution details. Therefore, this document fits the category of a Notice of Dividend Amount (DIV) rather than an Annual Report or Earnings Release.
2023-05-29 Chinese
关于仿制药聚乙二醇3350散获得上市许可受理的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding the acceptance of a registration application for a generic drug by the National Medical Products Administration (国家药品监督管理局). It details the drug's basic information, regulatory status, and potential risks related to the approval process. The document is short (1102 characters) and serves as a notification of a regulatory event rather than a financial report or detailed corporate filing. It does not contain financial data, management changes, voting results, or other report types. It is an official regulatory announcement about a product approval process, fitting best under Regulatory Filings (RNS).
2023-05-24 Chinese
关于实际控制人减持公司股份达到1%的公告
Major Shareholding Notification Classification · 100% confidence The document is a formal announcement from a company regarding the reduction of shares held by its actual controller and related parties. It details the number of shares reduced, the time period of the reduction, the shareholder involved, and confirms compliance with relevant securities laws. The document is short (2805 characters) and focuses on a specific shareholding change event rather than financial results or management discussion. It does not contain financial statements or detailed financial analysis. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds.
2023-05-23 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.